Injectable Administration Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Injectable Administration Systems
During the past 30 years, manufacturers have developed sophisticated packaging and delivery systems to support the requirements of traditional and complex biologics. Highest among the requirements during this time has been the increased focus on quality and cleanliness. This article discusses the evolution of packaging and delivery systems for injectable administration systems as the pharmaceutical and biotechnology industry evolved during the past 30 years. It also explores the future of packaging and..


Pharmaceutical Technology


A discussion of the past should be more than an exercise in historical review. It should provide a look at where we were as context for measuring how we have evolved and as pretext for predicting where we are going. Such is the case when looking back over 30 years at the development of packaging and delivery systems for injectable drug products. Although the components have changed very little in appearance, the material science and manufacturing technologies that go into their creation have undergone significant advancement.

The drive for quality and cleanliness

The most notable change to pharmaceutical packaging and packaging components during the past 30 years has been the rapidly increasing emphasis on closure cleanliness. Pharmaceutical manufacturers must ensure the purity of their drugs and provide products that are safe for patients and for those administering the drug. To this end, manufacturers specify packaging systems and components that eliminate, as much as possible, the risks to quality that stem from particulates, processing aides, extractables, and leachables.

This emphasis on cleanliness has been driven primarily by the increased number of biopharmaceuticals. This is not to imply that the industry was not quality-focused 30 years ago. On the contrary, the industry has a strong reputation for product purity. During these three decades, however, standards for packaging systems and components have evolved to meet the requirements for containing and delivering increasingly sophisticated drug products.

As pharmaceutical product development and manufacturing have improved since 1977, so, too, have delivery systems and components. Today, component manufacturing in classified areas and cleanrooms (up to Class 100 [ISO 5]) is commonplace. Thirty years ago, manufacturing proceeded in environments that were far from clean in the pharmaceutical sense. Component manufacturers now operate in environments conforming to current good manufacturing practice (CGMP) regulations, whereas 30 years ago, adherence to CGMPs was not required. As another example, ultrahigh quality now can be achieved with sophisticated electronic vision inspection, whereas 30 years ago, quality was highly dependent on the vision of plant employees.

The difference in component manufacturing between now and 30 years ago is astounding to those who are not familiar with the processes. Although the manufacturing processes then and now appear nearly identical, the technologies and systems behind the processes are radically different. For example, today's elastomer manufacturing facility is extremely high-tech. From the receipt of raw materials to the shipping of final products, every step is documented and measured to ensure traceability. These procedures are in place to ensure a high-quality product is delivered. Quality encompasses everything from traceability throughout the manufacturing process through the collection of in-process data and the improved cleanliness of the final product.

A visitor to a plant in 1977 would find an operation that bore scant resemblance to a pharmaceutical manufacturing facility. Thirty years ago, primary packaging components—that is, components such as stoppers and syringe plungers in contact with the packaged drug—were manufactured from elastomeric materials, many of which contained dry natural rubber. The manufacturing process consisted of blending the raw materials to form a sheet of rubber. The individual parts were formed by compression molding. A molded sheet could have hundreds or even thousands of individual parts that were trimmed in a die press. Some trimmed parts were washed, and others were packed in plastic bags for shipping to the customer. The components were frequently treated with silicone oil as a means of overcoming the tackiness inherent in an elastomeric product. Without some form of lubrication, the components would not process in a pharmaceutical filling line. Silicone oil, however, can transfer from the closure to the drug product.

To reduce reliance on silicone oil, component manufacturers developed films and coatings that provided lubricity for filling-line performance and provided a barrier against extractables. In the 1970s, a fluorinated ethylene-propylene (FEP) coating was applied to the drug contact side of serum stoppers, providing both a barrier and lubricity. The film adheres readily to the flat surface of a serum stopper or syringe plunger, but it cannot be applied to the more complex geometric shapes of lyophilization stoppers. To solve this problem, component manufacturers used films made from other fluorocarbon materials. These materials are conformable and provide excellent barrier protection. Further, fluoro-elastomer films have superior lubricity properties.

Another option for enhancing component performance on filling lines is a crosslinkable siloxane-based coating that is cured on the surface of elastomer components by ultraviolet light. This type of coating provides lubricity but does not have barrier properties.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here